市场概况

Biopsies are an important medical procedure where doctors extract cells or tissues from a patient’s body in order to examine them under a microscope. This closer inspection of samples provides critical information to help identify diseases and guide treatment decisions. By taking a small piece of suspect organs, tumors or lesions, pathologists can study the sampled cells and tissues at a microscopic level. This detailed evaluation allows them to discern abnormal cells and detect conditions that may otherwise go unnoticed. Examining samples directly reveals definitive answers about infection, cancer or other underlying issues in ways that routine blood tests simply cannot match.

The global biopsy devices market is poised for robust expansion between 2023 和 2029. The market is projected to grow at a compound annual growth rate of 8.3% over this period, adding over $2.2 billion in incremental value.

There are several drivers underpinning this positive outlook:
Rising incidence of cancer cases worldwide is directly increasing the number of biopsy procedures conducted each year. Biopsies provide a definitive tissue-based diagnosis that is essential for determining appropriate treatment plans. 所以, growth in cancer prevalence will propel biopsy device adoption in parallel.
Beyond cancer diagnosis, biopsies are routinely used to examine a wide array of health conditions spanning infections, kidney disorders, joint inflammation, skin diseases and others. This diverse scope of applications sustains constant demand among healthcare facilities.
Implementation of public awareness campaigns and screening programs aimed at early cancer detection are being rolled out globally. Subsidies and favorable reimbursement policies additionally improve biopsy access and affordability. These factors serve to further stimulate procedure volumes.

该报告涵盖了市场规模和增长, 分割, 区域细分, 竞争格局, trends and strategies for global biopsy devices market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

该行业报告提供了全球市场的市场估计和预测, 接下来是对产品的详细分析, biopsy type, guidance technique, anatomy, 疾病类型, 最终用户, 和地区.

By Product
Biopsy Devices
Consumables
服务

By Biopsy Type
Tissue Biopsy
Liquid Biopsy

By Guidance Technique
Ultrasound-Guided Biopsy
Stereotactic Guided Biopsy
MRI-Guided Biopsy
CT Guided Biopsy
其他的

By Disease Type
Cancer
Infections
Autoimmune Disorders
其他的

By Anatomy
Abdominal Biopsy
Bone Biopsy
Breast Biopsy
Liver Biopsy
Lung Biopsy
Prostate Biopsy
Uterus/Cervix/Ovary Biopsy
其他的

By End User
医院 & 诊所
Diagnostic & Imaging Centers
其他的

按地区
北美
欧洲
亚太
世界其他地区

Analyzing product segments, liquid biopsy accounted for the largest revenue share in the global biopsy devices market in 2022. Liquid biopsies analyze blood samples to detect circulating cancer cells and DNA, enabling non-invasive diagnostics and monitoring. This emerging segment is forecast to see robust adoption growth given benefits like minimal invasiveness, repeat testing ability, and suitability for screening and companion diagnostics.

By anatomy, breast biopsies dominated global biopsy device utilization in 2022. This predominance is attributed to:
High Incidence – Breast cancer is the most prevalent cancer in women, driving biopsy demand for diagnosis.
Screening – Guidelines recommend regular mammogram screening for women above 40 or 50 based on risk factors. Further testing via biopsy is common.
Monitoring – Biopsies help track disease progression and treatment efficacy in breast cancer patients through the course of care.
Risk Assessment – Where mammograms and ultrasounds are inconclusive, breast biopsies provide definitive pathology results to determine benign or malignant growths and guide decisions.
Genomic Testing – Biopsies allow genomic characterization of breast tumors to select optimal personalized therapies.
Technological enhancements like vacuum-assisted systems, MRI-guided procedures and minimally invasive approaches have expanded breast biopsy capabilities while reducing patient discomfort.

地理上, 北美地区占据最大的收入份额 2022, aided by high adoption of advanced biopsy systems, rising utilization, favorable reimbursements and easy accessibility. A developed healthcare infrastructure and focus on early cancer detection also advantage the region. Asia Pacific is expected to exhibit rapid growth fueled by improving healthcare access, growing diagnostics demand and rising cancer incidence. Though Europe represents a mature market, advancements in biopsy technology will support steady expansion.

主要公司及竞争格局

The global biopsy devices market report offers detailed information on several market vendors, including Agilent Technologies, 公司, Argon Medical Devices, 公司, 乙. Braun Holding GmbH and Co. 公斤, 贝克顿, 迪金森公司, BGI Group Limited, Biocept, 公司, Bio-Rad 实验室, 公司, 波士顿科学公司, 康德乐, 公司, CONMED Corporation, Cook Group Incorporated, Dxcover Limited, Elypta AB, F. 罗氏霍夫曼公司, Fujifilm Holdings Corporation, GE HealthCare Technologies, 公司, 全息, 公司, 照明公司, 公司, INRAD Inc., Integra Lifesciences Corporation, 美敦力公司, Micronoma Inc., Ningbo Xinwell Medical Technology Co., 有限公司, 奥林巴斯公司, 凯杰公司, Revvity, 公司, Siemens Healthineers AG, 史赛克公司, Sysmex Corporation, 赛默飞世尔科技公司, Zhejiang Kindly Medical Devices Co., 有限公司, 除其他外. 在这份报告中, 全面分析关键参与者及其策略，以了解市场的竞争前景.

报告范围

To analyze and forecast the market size of the global biopsy devices market.
To classify and forecast the global biopsy devices market based on product, biopsy type, guidance technique, anatomy, 疾病类型, 最终用户, 地区.
To identify drivers and challenges for the global biopsy devices market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global biopsy devices market.
To identify and analyze the profile of leading players operating in the global biopsy devices market.

为什么选择这份报告

Gain a reliable outlook of the global biopsy devices market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.